Skye Bioscience, Inc. Common Stock (SKYE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.83M
Last updated: Nov 17, 2026 at 11:03 AM ET
Skye Bioscience, Inc. Common Stock (SKYE) Competitors
The companies most similar to Skye Bioscience, Inc. Common Stock are PharmaCyte Biotech (PMCB), CNS Pharmaceuticals (CNSP) and Ensysce Biosciences (ENSC). By market cap, Skye Bioscience, Inc. Common Stock ranks 5th of the 13 companies on this page; Ensysce Biosciences (ENSC) is the largest at $8.14M.
Peer Comparison
SKYE's ROIC of -3685.3% is below the peer median of -247.2%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Skye Bioscience, Inc. Common Stock (SKYE) | $4.83M | N/A | N/A | 0.0% | -3685.3% | 0.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ensysce Biosciences Inc (ENSC) | $8.14M | N/A | 1.2x | -280.5% | -260.6% | -15.1% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kiora Pharmaceuticals Inc (KPRX) | $5.44M | N/A | 6.2x | 0.0% | N/A | 0.0% | 0.00% |
| Exicure Inc (XCUR) | $7.07M | N/A | N/A | 0.0% | N/A | 928.0% | 0.00% |
| Azitra Inc (AZTR) | $3.69M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Calidi Biotherapeutics Inc. (CLDI) | $2.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| GRI Bio Inc. (GRI) | $3.72M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Purple Biotech (PPBT) | $2.65M | N/A | N/A | 0.0% | -156.2% | 0.0% | 0.00% |
| Peer median | $3.94M | N/A | 3.7x | 0.0% | -247.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Skye Bioscience, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Ensysce Biosciences Inc (ENSC) | Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. | ENSC competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| Kiora Pharmaceuticals Inc (KPRX) | Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative... | KPRX competitors |
| Exicure Inc (XCUR) | Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases... | XCUR competitors |
| Azitra Inc (AZTR) | Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live... | AZTR competitors |
| Calidi Biotherapeutics Inc. (CLDI) | Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. | CLDI competitors |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| GRI Bio Inc. (GRI) | GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. | GRI competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| Purple Biotech (PPBT) | Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United... | PPBT competitors |
Frequently Asked Questions About SKYE
Who are Skye Bioscience, Inc. Common Stock's main competitors?
The companies most similar to Skye Bioscience, Inc. Common Stock include PharmaCyte Biotech (PMCB), CNS Pharmaceuticals (CNSP), Ensysce Biosciences (ENSC), Processa Pharmaceuticals (PCSA) and Kiora Pharmaceuticals (KPRX), listed from the closest match.
Who is Skye Bioscience, Inc. Common Stock's biggest competitor?
Ensysce Biosciences (ENSC) is the largest of the similar companies at $8.14M; PharmaCyte Biotech (PMCB) is the closest match by business profile, size, sector and industry.
How does SKYE stock compare with its competitors?
SKYE's net margin is 0.0% against a peer median of 0.0%.
Which of Skye Bioscience, Inc. Common Stock's competitors pays a higher dividend?
Skye Bioscience, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Skye Bioscience, Inc. Common Stock bigger than its competitors?
No. Skye Bioscience, Inc. Common Stock is 5th by market cap among the 13 companies on this page; the largest is Ensysce Biosciences (ENSC) at $8.14M.
SKYE pages: Overview, Earnings, Forecast, Financials, Competitors